| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2017-12-11 |
复牌提示：
2017-12-11 08:28:46 停牌，复牌日期 2017-12-12 00:00:01
|
| 2017-12-11 |
详情>>
内部人交易：
Dere Willard H等共交易18笔
|
| 2017-11-14 |
详情>>
股本变动：
变动后总股本2651.41万股
|
| 2017-11-14 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-0.74美元,归母净利润-1908.5万美元,同比去年增长12.22%
|
| 2017-08-01 |
详情>>
业绩披露：
2017年中报每股收益-0.51美元,归母净利润-1281.6万美元,同比去年增长12.32%
|
| 2017-05-09 |
详情>>
业绩披露：
2017年一季报每股收益-0.28美元,归母净利润-668.3万美元,同比去年增长11.06%
|
| 2017-04-25 |
股东大会：
将于2017-06-20召开股东大会
会议内容 ▼▲
- 1.To elect the following seven (7) nominees to our Board of Directors as directors, each to hold office until the Company’s 2018 annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal:
Eckard Weber, M.D.
Nina Kjellson
Steven P. James
Anne M. VanLent
Wendell Wierenga, Ph.D.
Willard Dere, M.D.
Linda S. Grais, M.D.
2.To hold a non-binding, advisory vote on the compensation of our named executive officers;
3.To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our 2017 fiscal year;
4.To transact such other business as may properly be brought before the meeting.
|
| 2017-03-14 |
详情>>
业绩披露：
2016年年报每股收益-1.22美元,归母净利润-2689.5万美元,同比去年增长-1.41%
|
| 2017-03-14 |
详情>>
业绩披露：
2014年年报每股收益-1.34美元,归母净利润-2342.5万美元,同比去年增长-33.75%
|
| 2016-11-02 |
详情>>
业绩披露：
2016年三季报(累计)每股收益-1.01美元,归母净利润-2174.2万美元,同比去年增长-11.8%
|
| 2016-08-04 |
详情>>
业绩披露：
2016年中报每股收益-0.69美元,归母净利润-1461.7万美元,同比去年增长-13.56%
|
| 2016-08-04 |
详情>>
业绩披露：
2015年中报每股收益-0.65美元,归母净利润-1287.2万美元,同比去年增长-14.03%
|
| 2016-05-03 |
详情>>
业绩披露：
2016年一季报每股收益-0.36美元,归母净利润-751.4万美元,同比去年增长-12.98%
|
| 2016-04-22 |
股东大会：
将于2016-06-14召开股东大会
会议内容 ▼▲
- 1.To elect the following seven (7) nominees to our Board of Directors as directors, each to hold office until the Company's 2017 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal:
Eckard Weber, M.D.
Linda S. Grais, M.D.
Steven P. James
Nina Kjellson
Michael Powell, Ph.D.
Anne M. VanLent
Wendell Wierenga, Ph.D.
2.To hold a non-binding, advisory vote on the compensation of our named executive officers;
3.To hold a non-binding, advisory vote on the frequency of future advisory votes on the compensation of our named executive officers;
4.To approve the Company's Fourth Amended and Restated 2011 Stock Option and Incentive Plan, which includes, among other things, an increase in the number of shares reserved for issuance by 1,400,000;
5.To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our 2016 fiscal year;
6.To transact such other business as may properly be brought before the meeting.
|
| 2016-03-11 |
详情>>
业绩披露：
2015年年报每股收益-1.32美元,归母净利润-2652.2万美元,同比去年增长-13.22%
|
| 2015-11-05 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-0.98美元,归母净利润-1944.7万美元,同比去年增长-8.7%
|
| 2015-04-24 |
股东大会：
将于2015-06-18召开股东大会
会议内容 ▼▲
- 1.To elect the following seven (7) nominees to our Board of Directors as directors, each to hold office until the Company's 2016 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal:Eckard Weber, M.D.;Linda S. Grais, M.D.;Steven P. James;Nina Kjellson;Michael Powell, Ph.D.;Anne M. VanLent;Wendell Wierenga, Ph.D.
2.To hold a non-binding, advisory vote on the compensation of our named executive officers;
3.To approve the Company's Third Amended and Restated 2011 Stock Option and Incentive Plan, which includes, among other things, an increase in the number of shares reserved for issuance by 1,300,000;
4.To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our 2015 fiscal year;
5.To transact such other business as may properly be brought before the meeting.
|
| 2014-04-29 |
股东大会：
将于2014-06-11召开股东大会
会议内容 ▼▲
- 1. To elect the following nine (9) nominees to our Board of Directors as directors, each to hold office until the Company's 2015 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal:
Eckard Weber, M.D. Jean-Paul Castaigne, M.D.
Lars G. Ekman, M.D., Ph.D. Linda S. Grais, M.D.
Nina Kjellson Michael Powell, Ph.D.
Franck S. Rousseau, M.D. Anne M. VanLent
Wendell Wierenga, Ph.D.
2. To hold a non-binding, advisory vote on the compensation of our named executive officers;
3. To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our 2014 fiscal year;
4. To transact such other business as may properly be brought before the meeting.
|
| 2013-11-15 |
股东大会：
将于2013-12-19召开股东大会
会议内容 ▼▲
- 1. To elect the following nine (9) nominees to our Board of Directors as directors, each to hold office until the Company's 2014 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal:
Eckard Weber, M.D. Jean-Paul Castaigne, M.D.
Lars G. Ekman, M.D., Ph.D. Linda S. Grais, M.D.
Nina Kjellson Michael Powell, Ph.D.
Franck S. Rousseau, M.D. Pratik Shah, Ph.D.
Anne M. VanLent
2. To hold a non-binding, advisory vote on the compensation of our named executive officers
3. To approve an amendment and restatement of the Company's Amended and Restated 2011 Stock Option and Incentive Plan, which changes the name of the plan to the Ocera Therapeutics, Inc. Second Amended and Restated 2011 Stock Option and Incentive Plan and increases the number of shares available for issuance by 2,000,000 shares;
4. To ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our 2013 fiscal year;
5. To transact such other business as may properly be brought before the meeting.
|
| 2013-08-14 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2013-06-10 |
股东大会：
将于2013-07-15召开股东大会
会议内容 ▼▲
- 1. To approve the issuance of Tranzyme's common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated as of April 23, 2013, by and among Tranzyme, Terrapin Acquisition, Inc., a wholly owned subsidiary of Tranzyme, and Ocera Therapeutics, Inc., or Ocera.
2. To approve the issuance of approximately $20.0 million in shares of Tranzyme's common stock to existing investors in Ocera in a private investment in public equity, or PIPE, transaction pursuant to a securities purchase agreement dated as of April 23, 2013, by and among Tranzyme and the investors named therein.
3. To approve amendments to Tranzyme's certificate of incorporation to effect a reverse stock split of Tranzyme's common stock and related matters.
4. To approve an amendment to Tranzyme's certificate of incorporation to change the name of Tranzyme to "Ocera Therapeutics, Inc."
5. To consider and vote upon an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1, 2, 3 and 4.
|